natgillin/translations-raw huggingface dataset:
The systemic bioavailability of robenacoxib tablets was 49% without food.
Sistemska biorazpoložljivost tablet robenakoksiba je bila brez hrane 49 %.
TARGET SPECIES Cats and dogs.
CILJNE ŽIVALSKE VRSTE Mačke in psi.
SPECIAL STORAGE CONDITIONS Store below 25 °C.
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi pod 25 °C.
The following number of tablets should be given once daily at the same time every day.
Enkrat dnevno dajte naslednje število tablet, vsak dan ob istem času.
Thereafter it is recommended to continue regular monitoring, e.g. every 3-6 months.
8 tednih, v nadaljevanju pa je priporočljiv nadzor vsake 3-6 mesecev.
In two clinical trials in (mainly indoor) cats with chronic musculo-skeletal disorder, robenacoxib increased the activity and improved subjective scores of activity, behaviour, quality of life, temperament and happiness of the cats.
V dveh kliničnih preizkusih pri (večinoma notranjih) mačkah s kroničnimi mišičnoskeletnimi obolenji je robenakoksib povečal aktivnost in izboljšal subjektivno ocenjeno aktivnost, obnašanje, kvaliteto življenja, temperament in zadovoljstvo mačk.
Robenacoxib also had no detrimental effects on cartilages or joints.
Robenakoksib tudi ni imel škodljivih vplivov na hrustanec in sklepe.
For long term therapy, liver enzymes should be monitored at the start of therapy, e.g. after 2, 4 and 8 weeks.
Pri dolgotrajnem zdravljenju je treba nadzirati jetrne encime na začetku zdravljenja, npr. po 2, 4 in
It is a potent and selective inhibitor of the cyclooxygenase 2 enzyme (COX-2).
Je močan in selektiven zaviralec encima ciklooksigenaza 2 (COX-2).
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each ml contains 20 mg robenacoxib as active substance and 1 mg sodium metabisulphite (E 223) as an antioxidant.
NAVEDBA UČINKOVIN(E) IN DRUGIH SESTAVIN Vsak ml vsebuje 20 mg robenakoksiba kot učinkovine in 1 mg natrijevega metabisulfita (E 223) kot antioksidanta.
Onsior tablets are easy to administer and well accepted by most cats.
Zdravilo Onsior tablete je enostavno za uporabo in ga večina mačk dobro sprejme.
The systemic bioavailability of robenacoxib tablets in dogs was 62% with food and 84% without food.
Sistemska biorazpoložljivost tablet robenakoksiba pri psih je bila s hrano 62 % in brez hrane 84 %.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
DATUM ZADNJE ODOBRITVE NAVODIL ZA UPORABO Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) (http://www.ema.europa.eu/).
As anaesthetics may affect renal perfusion, the use of parenteral fluid therapy during surgery should be considered to decrease potential renal complications when using NSAIDs peri-operatively.
Ker anestetiki lahko vplivajo na perfuzijo ledvic, je treba upoštevati uporabo parenteralne tekočinske terapije med operativnim posegom za zmanjšanje morebitnih ledvičnih zapletov, če se perioperativno uporabljajo zdravila iz skupine NSAID.
In healthy cats treated with or without the diuretic furosemide, concomitant administration of Onsior with the ACE inhibitor benazepril for 7 days was not associated with any negative effects on plasma aldosterone concentrations, plasma renin activity or glomerular filtration rate.
Pri zdravih mačkah, zdravljenih z ali brez diuretika furosemida, 7-dnevna hkratna uporaba zdravila Onsior in ACE inhibitorja benazeprila ni bila povezana z nikakršnimi negativnimi učinki na plazemske koncentracije aldosterona, plazemsko aktivnost renina ali hitrost glomerularne filtracije.
Onsior tablets are flavoured and are taken voluntarily by most dogs.
Zdravilo Onsior tablete so tablete z okusom in jih večina psov sprejme prostovoljno.
Clinical field studies showed that robenacoxib was well-tolerated by most cats for up to 12 weeks.
Klinične terenske študije so pokazale, da večina mačk dobro prenaša robenakoksib do 12 tednov.
Manufacturer responsible for the batch release: Elanco France S.A.S
Proizvajalec, odgovoren za sproščanje serij: Elanco France S.A.S.
Clear, colourless to slightly coloured (pink) liquid.
Bistra, brezbarvna do rahlo obarvana (roza) tekočina.
The biological relevance of increased QT intervals outside of normal variations observed following overdose of robenacoxib is unknown.
Klinični pomen podaljšanih QT intervalov zunaj normalnih sprememb, opaženih po prevelikem odmerjanju robenakoksiba, ni znan.
If use cannot be avoided, these animals require careful monitoring and fluid therapy.
Če se uporabi v takih primerih ne morete izogniti, potrebujejo te živali strog veterinarski nadzor in tekočinsko terapijo.
Diarrhoea, soft and dark faeces or reduced appetite were uncommon.
Diareja, mehko in temno blato ali zmanjšan apetit so bili opisani občasno.
The solution for injection is a clear, colourless to slightly coloured (pink) liquid.
Raztopina za injiciranje je bistra, brezbarvna do rahlo obarvana (roza) tekočina.
The pharmacokinetics of robenacoxib do not differ between male and female cats.
Farmakokinetika robenakoksiba se med mačkami in mački ne razlikuje.
No relevant effects on body weight, bleeding time or evidence of any gastrointestinal, kidney or liver toxicity were observed.
Opazili niso nikakršnih pomembnih učinkov na telesno maso, čas krvavitve ali prisotnost kakršnekoli toksičnosti na prebavila, ledvice ali jetra.
Accumulation of metabolites has not been tested.
Akumulacija presnovkov ni bila raziskana.
Bioaccumulation of metabolites has not been tested.
Bioakumulacija presnovkov ni bila raziskana.
After surgery in cats, once daily treatment may be continued at the same dosage and at the same time every day for up to 2 days.
Po operativnem posegu pri mačkah lahko še dva dni nadaljujete zdravljenje z enim odmerkom zdravila na dan, v enakem odmerku in ob istem času vsak dan.
Concurrent use of other active substances that have a high degree of protein binding may compete with robenacoxib for binding and thus lead to toxic effects.
Ob sočasni uporabi drugih učinkovin, ki se močno vežejo na plazemske proteine, lahko pride do tekmovalnosti z robenakoksibom pri vezavi in posledično do toksičnih učinkov.
In most cases there were no clinical signs and the liver enzyme activities either stabilised or decreased with continued treatment.
V večini primerov ni bilo prisotnih kliničnih znakov, z nadaljevanjem zdravljenja se je aktivnost jetrnih encimov stabilizirala ali zmanjšala.
Concomitant treatment with medicines displaying action on renal flow, e.g. diuretics or angiotensin converting enzyme (ACE) inhibitors, should be subject to clinical monitoring.
Sočasno zdravljenje z zdravili, ki vplivajo na ledvični pretok, npr. diuretiki ali inhibitorji angiotenzin konvertaze (ACE), mora biti pod strogim veterinarskim nadzorom.
After a subcutaneous administration of 1 mg/kg the systemic bioavailability is 69% in cats and 88% in dogs.
Po subkutanem injiciranju robenakoksiba v odmerku 1 mg/kg je bila sistemska biorazpoložljivost pri mačkah 69 % in pri psih 88 %.
Robenacoxib tablets are therefore COX-1 sparing at recommended doses in dogs.
Robenakoksib tablete torej nimajo vpliva na COX-1 v priporočenih odmerkih pri psih.
The cyclooxygenase 1 enzyme (COX-1) which has protective functions, e.g. in the digestive tract and kidneys, is not inhibited by robenacoxib.
Encima ciklooksigenaza 1 (COX-1), ki ima zaščitno funkcijo, npr. v prebavnem traktu in ledvicah, robenakoksib ne zavira.
Onsior 5 mg Onsior 10 mg Onsior 20 mg Onsior 40 mg
Onsior 5 mg Onsior 10 mg Onsior 20 mg Onsior 40 mg robenakoksib
For cats, Onsior solution for injection or tablets may be used interchangeably in accordance with the indications and directions of use approved for each pharmaceutical form.
Pri mačkah se lahko zamenljivo uporabi zdravilo Onsior raztopina za injiciranje ali zdravilo Onsior tablete, skladno z indikacijami in navodili za uporabo, odobrenimi za vsako farmacevtsko obliko.
Acute musculo-skeletal disorders: treat for up to 6 days.
2 tableti Akutna mišičnoskeletna obolenja: zdravite do 6 dni.
Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids, coxibs.
Farmakoterapevtska skupina: Nesteroidna protivnetna in protirevmatična zdravila, koksibi.
INDICATION(S) Not applicable.
INDIKACIJA(E) Ni smiselno.
7 tablets 14 tablets 28 tablets 70 tablets 30 x 1 tablets 60 x 1 tablets
7 tablet 14 tablet 28 tablet 70 tablet 30 x 1 tableta 60 x 1 tableta
Orthopaedic surgery: Give as a single oral treatment prior to orthopaedic surgery.
Ortopedski operativni posegi: Pred ortopedskim operativnim posegom dajte zdravilo v obliki enkratnega peroralnega odmerka.
Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and, accordingly, a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior.
Predhodno zdravljenje z drugimi zdravili s protivnetnim učinkom lahko povzroči dodatne ali povečane neželene učinke, zato je treba pred pričetkom zdravljenja z zdravilom Onsior zagotoviti vsaj 24-urno obdobje brez zdravljenja s takšnimi snovmi.
Tablets are round, beige to brown and non-divisible.
Tablete so okrogle, bež do rjave barve in nedeljive.
Number of tablets by size
Število tablet glede na velikost
Differences between robenacoxib and placebo were significant (P<0.05) for the client specific outcome measures, but did not reach significance (P=0.07) for the feline musculoskeletal pain index.
Razlike med robenakoksibom in placebom so bile signifikantne (P<0,05) za meritve izidov mačk, vendar niso bile signifikantne (P=0,07) za lestvico za merjenje mišičnoskeletne bolečine pri mačkah.
It selectively inhibits the cyclooxygenase 2 enzyme (COX-2), which is responsible for pain, inflammation or fever.
Selektivno zavira encim ciklooksigenazo 2 (COX-2), ki je odgovoren za bolečino, vnetje ali povišano telesno temperaturo.
2 tablets
2 tableti
Reversible inflammation at the injection site was noted in all groups (including controls) and was more severe in the 6 and 20 mg/kg dose groups.
Na mestu vboda je bilo pri vseh skupinah, vključno s kontrolnimi, opaziti vnetje (močneje pri skupinah z odmerkoma 6 mg/kg in
Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID).
Robenakoksib je nesteroidno protivnetno zdravilo (NSAID).
After subcutaneous administration, the terminal half-life from blood was 1.1 h in cats and 1.2 h in dogs.
Po subkutanem injiciranju je končni razpolovni čas 1,1 h pri mačkah in 1,2 h pri psih.
Repeated subcutaneous administration at dosages of 2-20 mg/kg produced no change in the blood profile, with neither bioaccumulation of robenacoxib nor enzyme induction.
Ponavljajoče se subkutano injiciranje odmerkov 2-20 mg/kg ni povzročilo sprememb v krvni sliki, bioakumulacije robenakoksiba ali indukcije encimov.
Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs).
Ne uporabite sočasno s kortikosteroidi ali drugimi nesteroidnimi protivnetnimi zdravili (NSAID).
10 mg tablet: BE 20 mg tablet: CD 40 mg tablet: BCK
5 mg tableta: AK 10 mg tableta: BE 20 mg tableta: CD 40 mg tableta: BCK
In small children, accidental ingestion increases the risk for NSAID adverse effects.
Nenamerno zaužitje pri majhnih otrocih poveča tveganje za pojav neželenih učinkov NSAID.
Onsior must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Zdravilo Onsior se ne sme uporabljati skupaj z drugimi zdravili iz skupine NSAID ali glukokortikoidi.
Vomiting and soft faeces were very common, decreased appetite and diarrhoea were common, and blood in the faeces was uncommon.
Zelo pogosto sta bila prisotna bruhanje in mehko blato, pogosto zmanjšan apetit in diareja, medtem ko je bila kri v blatu prisotna občasno.
At the recommended dosage (2 mg/kg), analgesic, anti-inflammatory and anti-pyretic effects were demonstrated in an inflammation model, and in clinical trials, robenacoxib reduced pain and inflammation in cats undergoing orthopaedic or soft tissue surgery.
V priporočenem odmerku (2 mg/kg) so bili pri vnetnem modelu vidni protibolečinski, protivnetni in antipiretični učinki, v kliničnih preizkusih pa je robenakoksib zmanjšal bolečino in vnetje pri mačkah, podvrženih ortopedskim operativnim posegom ali operativnim posegom na mehkih tkivih.
No safety data in the target population and no efficacy data in general exist for the combined treatment of robenacoxib and benazepril.
Za zdravljenje s kombinacijo učinkovin robenakoksiba in benazeprila pri ciljni populaciji ni podatkov o varnosti in učinkovitosti na splošno.
Do not use after the expiry date stated on the label or blister after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini ali pretisnem omotu za oznako »EXP«.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE NATURE/TYPE: Cardboard box
PODATKI NA ZUNANJI OVOJNINI VRSTA/TIP: Kartonska škatla
In the high dose group kidney weights were decreased and sporadically associated with renal tubular degeneration/ regeneration but not correlated with evidence of renal dysfunction on clinical pathology parameters.
V skupini z visokim odmerkom so opazili zmanjšanje mase ledvic in občasno povezavo z ledvično tubularno degeneracijo/regeneracijo, kar pa ni bilo povezano s prisotnostjo ledvične disfunkcije, ki bi se odražala na kliničnih patoloških parametrih.
A dose-dependent increase in the QT interval, a decreased heart rate and corresponding increased respiratory rate were observed in laboratory studies.
Pri laboratorijskih študijah so opazili od odmerka odvisno podaljšanje QT intervala, zmanjšan srčni utrip in odgovarjajočo povečano stopnjo dihanja.
In overdose studies conducted in cats, there was a dose-dependent increase in the QT interval.
Pri študijah prevelikega odmerjanja, narejenih na mačkah, so opazili od odmerka odvisno podaljšanje
Slight pain at injection site was commonly reported.
Rahla bolečina na mestu injiciranja je bila opisana pogosto.
Name and address of the manufacturers responsible for batch release
Ime in naslov proizvajalcev zdravila, odgovornih za sproščanje serij
Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID) of the coxib class.
Robenakoksib je nesteroidno protivnetno zdravilo (NSAID) iz skupine koksibov.
Concurrent administration of potentially nephrotoxic medicines should be avoided as there might be an increased risk of renal toxicity.
Izogibajte se sočasni uporabi potencialno nefrotoksičnih snovi, ker obstaja povečano tveganje toksičnega vpliva na ledvice.
In dogs treated up to 2 weeks no increases in liver enzyme activities were observed.
Pri psih, zdravljenih do 2 tednov, ni bilo opaziti porasta aktivnosti jetrnih encimov, vendar pa je bila ta pogosto povišana pri dolgotrajnem zdravljenju.
If use cannot be avoided, these cats require careful monitoring.
Če se uporabi v takih primerih ne morete izogniti, potrebujejo te mačke strog veterinarski nadzor.
In clinical trials robenacoxib tablets reduced the lameness and inflammation of dogs with chronic osteoarthritis.
V kliničnih preizkusih so tablete robenakoksiba zmanjšale šepanje in vnetje pri psih s kroničnim osteoartritisom.
The pharmacokinetics of robenacoxib injection do not differ between male and female cats and dogs, and are linear over the range of 0.25-4 mg/kg in dogs.
Farmakokinetika injiciranega robenakoksiba se med mačkami in psi ženskega in moškega spola ne razlikuje ter je pri psih pri odmerkih 0,25-4 mg/kg linearna.
In an inflammation model in cats, robenacoxib injection had analgesic, anti-inflammatory and anti-pyretic effects and a rapid onset of action (0.5 h).
Pri vnetnem modelu pri mačkah je robenakoksib v obliki injekcije učinkoval protibolečinsko, protivnetno in antipiretično, s hitrim nastopom učinka (0,5 h).
Multi-dose amber glass vial containing 20 ml solution for injection, closed with a rubber stopper and sealed with an aluminium cap. One vial packed in a cardboard box.
Večodmerna viala iz temnega stekla vsebuje 20 ml raztopine za injiciranje in je zaprta z gumijastim zamaškom in aluminijasto zaporko.
and a slightly lower AUC (1,069 ng·h/ml).
AUC (1383 ng·h/ml).
Tablets are round, beige to brown, non-divisible and with imprints “NA” on one side and “AK” on the other side.
Tablete so okrogle, bež do rjave barve, nedeljive in z vtisnjenima oznakama »NA« na eni in »AK« na drugi strani.
For long-term treatment, once a clinical response has been observed, the dose of Onsior can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic osteoarthritis may vary over time.
Pri dolgotrajnem zdravljenju lahko po vidnem kliničnem odzivu odmerek zdravila Onsior prilagodite na najnižji učinkovit individualen odmerek, pri tem pa upoštevajte, da se stopnja bolečine in vnetja,
Administer subcutaneously to cats or dogs approximately 30 minutes before the start of surgery, for example around the time of induction of general anaesthesia, at a dose of 1 ml per 10 kg of body weight (2 mg/kg).
Dajte subkutano mačkam ali psom približno 30 minut pred začetkom operativnega posega, npr. v času uvajanja splošne anestezije, v odmerku 1 ml na 10 kg telesne mase (2 mg/kg).
Moderate or severe pain at injection site was uncommon.
Zmerna ali huda bolečina na mestu injiciranja je bila opisana občasno.
COX-2 is the inducible form of the enzyme which is responsible for the production of mediators including PGE2 which induce pain, inflammation or fever.
COX-2 je inducibilna oblika encima, ki je odgovorna za sintezo mediatorjev, vključno s PGE2, ki inducirajo bolečino, vnetje ali povišano telesno temperaturo.
Each tablet contains 6 mg robenacoxib.
Vsaka tableta vsebuje 6 mg robenakoksiba.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
A. PROIZVAJALCI ZDRAVILA, ODGOVORNI ZA SPROŠČANJE SERIJ
Administer the solution subcutaneously to cats or dogs approximately 30 minutes before the start of surgery, for example around the time of induction of general anaesthesia, at a dose of 1 ml per 10 kg of body weight (2 mg/kg).
Raztopino dajte subkutano mačkam in psom približno 30 minut pred pričetkom operativnega posega, npr. v času uvajanja splošne anestezije, v odmerku 1 ml na 10 kg telesne mase (2 mg/kg).
Sodium metabisulphite (E 223)
robenakoksib 20 mg Pomožna snov: natrijev metabisulfit (E 223)
In case of accidental ingestion or self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
V primeru nenamernega zaužitja ali samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
Robenacoxib is excreted predominantly via the biliary route in cats (∼70%) and dogs (∼65%) and the remainder via the kidneys.
Pretežno se izloča z žolčem tako pri mačkah (∼ 70 %) kot pri psih (∼ 65 %), preostali del pa preko ledvic.
The recommended dose of robenacoxib is 1 mg/kg body weight with a range 1-2.4 mg/kg.
Priporočen odmerek robenakoksiba je 1 mg/kg telesne mase v območju 1-2,4 mg/kg.
INDICATION(S) For the treatment of pain and inflammation of chronic osteoarthritis in dogs.
INDIKACIJA(E) Za zdravljenje bolečine in vnetja v povezavi s kroničnim osteoartritisom pri psih.
(IC50 0.04 μM) as compared to COX-1 (IC50 7.9 μM).
kot za COX-1 (IC50 7,9 μM).
Pain at injection site was commonly reported.
Bolečina na mestu injiciranja je bila opisana pogosto.
In most cases the liver enzyme activities either stabilised or decreased with continued treatment.
Z nadaljevanjem zdravljenja se je v večini primerov aktivnost jetrnih encimov stabilizirala ali zmanjšala.
The recommended dose of robenacoxib is 1 mg/kg body weight with a range 1-2 mg/kg.
Priporočen odmerek robenakoksiba je 1 mg/kg telesne mase v območju 1-2 mg/kg.
COX-1 is the constitutive form of the enzyme and has protective functions, e.g. in the gastrointestinal tract and kidneys.
COX-1 je konstitutivna oblika encima, ki ima zaščitno funkcijo, npr. v prebavnem traktu in ledvicah.
If use cannot be avoided, these dogs require careful monitoring.
Če se uporabi v takih primerih ne morete izogniti, potrebujejo ti psi strog veterinarski nadzor.
Peak blood concentrations of robenacoxib are attained rapidly after subcutaneous injection in cats and dogs.
Po subkutanem injiciranju robenakoksiba so bile pri mačkah in psih maksimalne koncentracije v krvi hitro dosežene.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each tablet contains the following amount of robenacoxib and bears the imprint “NA” on one side and the following imprint on the other side:
NAVEDBA UČINKOVIN(E) IN DRUGIH SESTAVIN Vsaka tableta vsebuje naslednje količine robenakoksiba, z vtisnjeno oznako »NA« na eni strani in naslednjimi vtisnjenimi oznakami na drugi strani: robenakoksib/tableta Vtisnjene oznake 5 mg
Treatment should not exceed one dose (either tablet or injection) per day.
Zdravljenje ne sme preseči enega odmerka (tablet ali raztopine za injiciranje) na dan. Upoštevajte dejstvo, da je priporočen odmerek za vsako od farmacevtskih oblik različen.
Co-administration of robenacoxib non-flavoured tablets with food produced no delay in Tmax, but slightly lower values for Cmax (832 ng/ml) and AUC (782 ng·h/ml).
Pri vnosu robenakoksib tablet brez okusa, skupaj s hrano, ni prišlo do podaljšanja pri Tmax, ampak do rahlo nižje koncentracije Cmax (832 ng/ml) in AUC (782 ng·h/ml).
Robenacoxib persists longer and in higher concentrations at sites of inflammation than in blood.
Na vnetnih mestih ostaja robenakoksib dlje časa in v višjih koncentracijah kot v krvi.
In vivo, robenacoxib solution for injection produced marked inhibition of COX-2 activity and had no effect on COX-1 activity.
In vivo je robenakoksib raztopina za injiciranje povzročila vidno inhibicijo COX-2 aktivnosti, medtem ko na COX-1 aktivnost ni vplivala.
Increases in liver enzyme activities associated with clinical signs of anorexia, apathy or vomiting were uncommon.
Občasno je bila povečana aktivnost jetrnih encimov v povezavi s kliničnimi znaki anoreksije, apatije ali bruhanja.
For the treatment of pain and inflammation associated with acute or chronic musculoskeletal disorders in cats.
Za zdravljenje bolečine in vnetja v povezavi z akutnimi ali kroničnimi mišičnoskeletnimi obolenji pri mačkah.
The pharmacokinetics of robenacoxib do not differ between male and female dogs, and are linear over the range 0.5-8 mg/kg.
Farmakokinetika robenakoksiba se med psicami in psi ne razlikuje ter je pri odmerkih od 0,5 do 8 mg/kg telesne mase linearna.
In an in vitro whole blood assay in dogs, robenacoxib was approximately 140 fold selective for COX-2
In vitro raziskave celokupne krvi pri psih so pokazale, da je selektivnost robenakoksiba približno 140
In the in vitro whole blood assay in cats, the selectivity of robenacoxib was approximately 500 fold higher for COX-2 (IC50 0.058 μM) as compared to COX-1 (IC50 28.9 μM).
In vitro raziskave celokupne krvi pri mačkah so pokazale, da je selektivnost robenakoksiba približno 500-krat večja za COX-2 (IC50 0,058 μM) kot za COX-1 (IC50 28,9 μM).
After intravenous administration robenacoxib was rapidly cleared from blood (CL of 0.44 L/kg/h in cats and 0.81 L/kg/h in dogs) with an elimination t1/2 of 1.1 h in cats and 0.8 h in dogs.
Robenakoksib se po intravenskem dajanju iz krvi izloča hitro (CL 0,44 l/kg/h pri mačkah in 0,81 l/kg/h pri psih), z razpolovnim časom t1/2 1,1 h pri mačkah in 0,8 h pri psih.
In artificially induced inflammation in cats and dogs, robenacoxib reduced pain, inflammation and fever at the recommended doses with a rapid onset of action (1 h).
Pri umetno induciranih vnetjih pri mačkah in psih je robenakoksib v priporočenih odmerkih hitro (1 h) zmanjšal bolečino, vnetje in povišano telesno temperaturo.
STATEMENT OF ACTIVE SUBSTANCES 20 mg/ml Robenacoxib
20 mg/ml robenakoksiba
After oral administration of tablets, the terminal half-life from blood was 1.7 h. Robenacoxib persists longer and at higher concentrations at sites of inflammation than in blood.
Po peroralnem vnosu tablet je končni razpolovni čas 1,7 h. Na vnetnih mestih ostaja robenakoksib dlje časa in v višjih koncentracijah kot v krvi.